Research Project on the Interaction Between Immune Function and Infectious Diseases in Older Adults and the Development of Prevention and Control Strategies
As population aging accelerates, infectious diseases have become a major factor affecting the health, quality of life, and survival outcomes of older adults. Immunosenescence, chronic low-grade inflammation (inflammaging), and dysbiosis of the respiratory and gut microbiota are considered important mechanisms underlying increased susceptibility to infection and a higher risk of severe disease in older adults. However, the interactions among these factors and their impact on infection-related outcomes remain incompletely understood.
Building upon a previously established pilot cohort of older adults, this study aims to further identify and validate key biological characteristics and risk factors associated with infectious diseases through large-scale population follow-up. A large prospective cohort of older adults will be established, while retrospective healthcare data collected since 2019 will also be integrated. Demographic information, comorbidities, medication history, infection-related clinical data, and biological specimens, including blood, urine, fecal, and respiratory samples, will be collected for long-term longitudinal follow-up. By integrating immunological assessments, immune repertoire analyses, microbiome profiling, and other multi-omics technologies, this study will systematically evaluate the effects of immunosenescence, respiratory and gut microbiome alterations, and environmental and climatic factors on the occurrence, severity, and prognosis of infectious diseases in older adults. The study aims to identify key biomarkers and microbial signatures associated with infection risk and to develop risk prediction and early warning models for infectious diseases in older adults, thereby providing scientific evidence for precision prevention, optimized clinical management, and public health decision-making in aging populations.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Jingwen Ai
- Telefoonnummer: 17317958269
- E-mail: jingwenai1990@126.com
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- General Cohort Inclusion Criteria
- Adults aged 60 years or older who are in generally good health, defined as having no severe organ dysfunction that significantly affects daily living activities (e.g., decompensated heart, liver, or kidney failure), adequate nutritional status (without significant wasting or malnutrition), and the ability to communicate and comply with study procedures.
- Male or female.
- Able to understand the study and voluntarily provide written informed consent.
Infection Cohort Inclusion Criteria
- Adults aged 60 years or older, regardless of sex.
- Patients with an infectious disease diagnosed by a qualified clinician.
Exclusion Criteria:
General Cohort Exclusion Criteria
- Refusal to participate in this study.
- Any other condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment.
Infection Cohort Exclusion Criteria
- Final primary diagnosis is a non-infectious disease (e.g., connective tissue disease, malignancy, or other non-infectious conditions).
- Positive culture results determined by the treating clinician to represent colonization or contamination rather than true infection.
- Refusal to participate in this study.
- Critically ill patients or those unable to cooperate with specimen collection procedures.
- Any other condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
|---|
|
Older Adults Without Infection
Community-dwelling adults aged 60 years and older who do not develop any clinically diagnosed infectious disease during the follow-up period.
|
|
Older Adults With Infection
Community-dwelling adults aged 60 years and older who develop clinically diagnosed infectious diseases during follow-up.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Occurrence of infectious disease outcomes in older adults
Tijdsspanne: Baseline to 3 years
|
Occurrence of infectious disease outcomes in older adults, including all-cause mortality, infection-related mortality, first infectious disease event, and progression to severe infection.
|
Baseline to 3 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
High-Frequency Infection Status (≥6 Infections per Year)
Tijdsspanne: Baseline to 3 Years
|
Defined as an average of six or more infectious episodes per year during follow-up.
|
Baseline to 3 Years
|
|
Pathogen-Specific Infection Events
Tijdsspanne: Baseline to 3 Years
|
Infectious disease events caused by specific pathogens, used to evaluate pathogen distribution and temporal trends.
|
Baseline to 3 Years
|
|
Changes in Immune Function Biomarkers
Tijdsspanne: Baseline to 3 Years
|
Assessment of longitudinal changes in immune cell subsets and immune function status.
|
Baseline to 3 Years
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Changes in Metabolomic and Microbiome Profiles
Tijdsspanne: Baseline to 3 Years
|
Assessment of longitudinal changes in metabolomic profiles and gut and respiratory microbiome characteristics associated with infection risk and disease severity.
|
Baseline to 3 Years
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 20260306-001
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .